High-Impact Clinical Trials

Hall D

Moderators:
Michel Chonchol, MD, and T. Alp Ikizler, MD, FASN

10:30 a.m. HALT Progression of Polycystic Kidney Disease (HALT PKD) Trials: Primary Results of a 2x2 Factorial Trial in Early Stage CKD — Arlene B. Chapman, Kaleab Z. Abebe, Ronald D. Perrone, Vicente E. Torres, William E. Braun, Theodore I. Steinman, Franz Winklhofer, Godela M. Brosnahan, Peter G. Czannecki, Marie C. Hogan, Dana Miskulin, Frederic F. Rahbari-Oskoui, Jared J. Grantham, Peter C. Harris, Michael F. Flessner, Kyongtlae Ty Bae, Charity G. Moore, Robert W. Schrier. Atlanta, GA.


10:44 a.m. Questions and Answers

10:50 a.m. ADVANCE-ON: Long-Term Benefits of Intensive Glucose Control for End-Stage Kidney Disease — Vlado Perkovic, Mark E. Cooper, Mark Woodward, John P. Chalmers, Michel Marre, Sophia Zoungas. Sydney, Australia.

11:00 a.m. Questions and Answers

11:04 a.m. Renal Efficacy and Safety of Anti-TGF-β1 Therapy in Patients with Diabetic Nephropathy — James R. Voelker, Paul H. Berg, Matthew Sheetz, Kevin L. Duffin, Julia Lewis, Tom Greene, Philippe Zououi. Carmel, IN.

11:14 a.m. Questions and Answers

11:18 a.m. Randomized Clinical Trial of Ergocalciferol Supplementation in 25 Vitamin D Deficient Hemodialysis Patients — Dana Miskulin, Hocine Tighouart, Karen M. Majchrzak, Richard S. Muther, Toros Kapoian, Doug Johnson, Daniel E. Weiner. Somerville, MA.

10:44 a.m. Questions and Answers


11:42 a.m. Questions and Answers

11:46 a.m. Six-Month Results of the RESCUE Trial: Fluency® Plus Endovascular Stent Graft versus PTA for In-Stent Restenosis — Alexander S. Yevzlin, Ivan D. Maya, Abigail Falk. Madison, WI.

11:56 a.m. Questions and Answers

12:00 p.m. Impact of Extended Weekly Hemodialysis Hours on Quality of Life and Clinical Outcomes: The ACTIVE Dialysis Multinational Trial — Meg J. Jardine, Li Zuo, Nicholas A. Gray, Janak Rashme de Zoyza, Christopher T. Chan, Martin P. Gallagher, Alan Cass, Vlado Perkovic. Campertown, Australia.

12:10 p.m. Questions and Answers

12:14 p.m. ACT-AKI: A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of AC607 for the Treatment of Acute Kidney Injury in Cardiac Surgery Subjects — Madhav Swaminathan, David Mazer, Glenn M. Chertow, David G. Warnock, Viken Paragamian, Robert M. Brenner. Durham, NC.

12:24 p.m. Questions and Answers
Late-Breaking Posters
Exhibit Halls A-C


SA-PO1092 A Randomized Multicomponent Intervention to Reduce Disparities in Transplant Referral: Interim Results from the RaDIANT Community Study — Rachel E. Patzer, Leighann Sauls, Jennifer C. Gander, M. Ahinee Amamoo, Laura Plantinga, Debra D. Evans, Eric M. Gibney, Laura L. Mulloy, Stephen O. Pastan. Atlanta, GA.

SA-PO1093 Envarsus XR (Once-Daily MeltDose Tacrolimus Tablets) Shows Continued Dose Reduction and Similar Efficacy and Safety vs. Prograf (Twice-Daily Tacrolimus Capsules) at Two-Years: Results of a Phase 3, Double-Blind, Randomized Study in De Novo Kidney Transplant Patients — Lionel Rostaing, Suphamai Bunnapradist. Toulouse Cedex, France.

SA-PO1094 Urgent-Start Peritoneal Dialysis versus Urgent-Start Hemodialysis: A Multicenter Clinical Trial — Arshia Ghaffari, Steven M. Brunelli, Michelle Cassin, Martin J. Schreiber. Los Angeles, CA.


SA-PO1096 The Utility of Photoplethysmographic Measures of Cardiovascular Stress to Detect Intradialytic Hypotension — Dana Miskulin, Klemens B. Meyer, Mary kay Deck, Anne M. Brumfield, Rajat Deo, John E. Moran. Somerville, MA.

SA-PO1097 The Beta-Blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial of Carvedilol versus Placebo in Patients Receiving Dialysis — Matthew Allan Roberts. Blackburn, VIC, Australia.


SA-PO1099 Effect of Patiromer on Hyperkalemia in Patients with Diabetic Nephropathy: Results of a 1-Year Randomized Trial — George L. Bakris, Bertram Pitt, Martha Mayo, Dahlia Garza, Yuri Stasiv, Lance Berman, David A. Bushinsky. Chicago, IL.

SA-PO1100 ZS-9 Effectively Reduces Potassium Levels in Hyperkalemic Diabetic Patients Who Have Both Renal Impairment and a History of Heart Failure — David K. Packham, Simon D. Roger, Mohamed A. El-Shahawy, Wajez Y. Qunibi, Henrik S. Rasmussen, Bhupinder Singh, Alex Yang, Phil L. Lavin, Adrian Covic. Eltham Melb, VIC, Australia.


SA-PO1104  Phase III Study of ASP1585 (Bixalomer) – Randomized, Double-Blind, Placebo-Controlled Study in Chronic Kidney Disease Patients with Hyperphosphatemia Not on Dialysis — Tadao Akizawa, Hideki Origasa, Chisato Kameoka, Junko Tsukada, Kentarou Kuroishi, Yusuke Yamaguchi. Tokyo, Japan.

SA-PO1105  2MD, a New Treatment for Secondary Hyperparathyroidism — Hector F. Deluca. Madison, WI.

SA-PO1106  Iron Isomaltoside 1000 (Monofer®) Compared to Oral Iron Sulphate in Patients with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) — Philip A. Kalra, Sunil Bhandari, Lars L. Thomsen. Salford, United Kingdom.

SA-PO1107  In-Hospital, Electronic Alerts for Acute Kidney Injury: A Randomized, Controlled Trial — Francis Perry Wilson, Michael G. Shashaty, Peter P. Reese, Yevgeniy Gitelman, Yuliya Borovskiy, Harold I. Feldman, Susan Ellenberg, Barry D. Fuchs. New Haven, CT.

SA-PO1108  A Randomized Trial of Home Video Monitoring by an Interprofessional Care Team on Outcomes in Patients with Chronic Kidney Disease — Areef Ishani, Juleen Christopher, Deirdre A. Palmer, Sara Otterness, Barbara Clothier, Sean Nugent, David Nelson, Mark E. Rosenberg. Minneapolis, MN.

SA-PO1109  Stent Treatment in Atherosclerotic Renal Artery Stenosis: Kidney Function and Clinical Events — Katherine R. Tuttle, Lance D. Dworkin, Barbara A. Greco, William L. Henrich, Michael Steffes, Kenneth A. Jamerson, Joseph I. Shapiro, Karol M Pencina, Joseph Massaro, Donald Cutlip, Sheldon W. Tobe, Timothy P. Murphy, Christopher J. Cooper, Ralph B. D’Agostino. Spokane, WA.